finanzen.net
20.05.2019 20:00
Bewerten
(0)

DGAP-News: Biom'up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City

DRUCKEN

DGAP-News: Biom'up / Key word(s): Conference
Biom'up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City

20.05.2019 / 20:00
The issuer is solely responsible for the content of this announcement.


Biom'up to Present at the RBC Capital Markets Global Healthcare Conference
on Tuesday May 21, 2019 in New York City

 

Saint-Priest, France, May 20, 2019 - 18h00 (CET) - Biom'up (the « Company »), specializing in surgical hemostasis, today announced that Etienne Binant, Chief Executive Officer, will host a fireside presentation to U.S. investors at the 2019 RBC Capital Markets Global Healthcare Conference. The session moderated by an analyst from RBC Equity Research, Zoe Karamanoli, is being held on Tuesday, May 21, 2019 at 11:30 a.m. (ET) at the InterContinental Barclay Hotel in New York City (USA).


Contacts

Biom'up
Chief Financial Officer
Jean-Yves Quentel
investisseurs@biomup.com
+33 4 86 57 36 10
MC Services AG
International Investor and Public Relations
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252-22
 

About Biom'up

Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom'up develops and commercializes hemostatic products based on patented biopolymers designed to simplify the surgeons practices for open and minimally invasive surgical procedures, including laparoscopic, in multiple specialties such as cardiac, general, and orthopedic surgery. The Company's lead product, HEMOBLASTTM Bellows and its laparoscopic applicator are marketed in Europe and the United States.

Since its creation, Biom'up has benefited from the support of prominent European and U.S. investors. The Company's shareholders include Bpifrance (including its Innobio fund), Gimv, Lundbeckfond, Athyrium Capital, Financière Arbevel and Invesco, as well as all the Company's management team. Biom'up successfully completed its IPO on Euronext Paris, raising EUR42.5 million in October 2017.

Since then, the Company carried out a EUR16 million capital increase in February 2018 and a EUR7.7 million capital increase by means of a private placement in December 2018. It also entered into a EUR25 million bond financing agreement with Athyrium, a U.S. fund specializing in innovative companies in the healthcare sector, in March 2018, that was brought to EUR28 million in December 2018.


About HEMOBLAST

HEMOBLAST Bellows is a hemostatic product to control bleeding in a broad range of open and minimally invasive surgical procedures including laparoscopy for multiple specialties such as cardiac, general, and orthopedic surgery.

Uncontrolled bleeding is a major surgical complication associated with higher mortality, longer hospitalization and higher rates of transfusions and reoperations. Beyond its impact on patient's health, this major complication causes excess costs in all surgical specialties and is a burden for hospital budgets across the globe. HEMOBLAST Bellows is the only surgical hemostatic agent approved by the FDA based on the validated SPOT GRADE(TM) Surface Bleeding Severity Scale (SBSS), which demonstrates the ability to control a range of bleeding from minimal (oozing), mild (pooling) and moderate (flowing) bleeding. HEMOBLAST Bellows is proven to control bleeding with flow rates up to 117 mL per minute. Due to its efficacy, versatility and ease of use, HEMOBLAST Bellows is quickly becoming a popular choice amongst U.S. surgeons looking for new options to control surgical bleeding challenges.

Biom'up obtained CE Marking for HEMOBLAST Bellows in December 2016. On the basis of compelling preliminary results (93% effectiveness at 6 minutes, compared with 74% for the control arm) in a major clinical trial, FDA approval for HEMOBLAST Bellows in December 2017, seven months ahead of the original plan. This allowed for the commercial roll-out of its lead product in the U.S. in the summer of 2018.

In July 2018, Biom'up additionally obtained CE Marking for its HEMOBLAST Bellows Laparoscopic Applicator designed to deliver the HEMOBLAST Bellows powder in all minimally-invasive procedures. In January 2019, the Company obtained the respective approval for HEMOBLAST Bellows Laparoscopic Applicator in the U.S. This has opened up new market segments, representing approximately 500,000 and 443,000 surgeries per year in Europe and the US respectively.

Currently the Company is working to expand the range of applications for HEMOBLAST Bellows. In addition, the approval from the Australian health authorities for the Company's lead product is expected during the second half of 2019.



20.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biom'up
8, allée Irène Joliot Curie
69800 Saint-Priest
France
Phone: +33 (0)4 86 57 36 10
Fax: +33 (0)4 37 69 00 84
E-mail: contact@biomup.com
Internet: www.biomup.com
ISIN: FR0013284080
WKN: A2H5VA
Listed: Regulated Unofficial Market in Berlin; London, Paris
EQS News ID: 813689

 
End of News DGAP News Service

813689  20.05.2019 

fncls.ssp?fn=show_t_gif&application_id=813689&application_name=news&site_id=smarthouse

Nachrichten zu BIOM'UP SA Reg S

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu BIOM'UP SA Reg S

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Wachstumsaktien im Fokus

Wie identifizieren Sie wachstumsstarke Aktien? Kai Knobloch erklärt heute Abend live, wie Sie die CASLIM-Methode anwenden und erfolgreich in Wachstumsaktien investieren - für Sie kostenlos! Jetzt kostenlos anmelden!
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

BIOMUP Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX freundlich -- Dow im Plus erwartet --Bitcoin nahe 13.000-Dollar-Marke -- Tesla dürfte wohl Rekordquartal verfehlen -- USA: Abkommen mit China zu 90 Prozent komplett -- FedEx, thyssenkrupp im Fokus

Anzeige gegen Brenntag nach umstrittenen Chemikalien-Lieferungen. Apple kauft zu. Infineon-Aktie und Siltronic-Papiere legen zu: Chipwerte erholen sich nach optimistischen Signalen von Micron. GfK: Konsumklima fällt zum zweiten Mal in Folge. Siemens: "Wir warnen nicht vor zu hohen Gewinnschätzungen".

Die 5 beliebtesten Top-Rankings

Promis
Diese Sternchen haben ihren eigenen Aktien-Index
Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das niedrigste Gehalt
Welche Branchen man besser meiden sollte.
DIe innovativsten Unternehmen
Diese Unternehmen sind am fortschrittlichsten
mehr Top Rankings

Umfrage

Die USA suchen Verbündete gegen den Iran. Sollte sich Deutschland einer solchen Allianz anschließen?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
Infineon AG623100
Microsoft Corp.870747
Amazon906866
BayerBAY001
TeslaA1CX3T
Lufthansa AG823212
Apple Inc.865985
Siemens AG723610
Barrick Gold Corp.870450
BASFBASF11
thyssenkrupp AG750000